Aptevo Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net income was USD 28.01 million compared to net loss of USD 7.93 million a year ago. Basic earnings per share from continuing operations was USD 5.55 compared to basic loss per share from continuing operations of USD 1.78 a year ago. Diluted earnings per share from continuing operations was USD 5.55 compared to diluted loss per share from continuing operations of USD 1.78 a year ago. Basic earnings per share was USD 5.58 compared to basic loss per share of USD 1.75 a year ago. Diluted earnings per share was USD 5.58 compared to diluted loss per share of USD 1.75 a year ago.
For the six months, net income was USD 20.31 million compared to net loss of USD 15.19 million a year ago. Basic earnings per share from continuing operations was USD 4.01 compared to basic loss per share from continuing operations of USD 3.51 a year ago. Diluted earnings per share from continuing operations was USD 4.01 compared to diluted loss per share from continuing operations of USD 3.51 a year ago. Basic earnings per share was USD 4.08 compared to basic loss per share of USD 3.39 a year ago. Diluted earnings per share was USD 4.08 compared to diluted loss per share of USD 3.39 a year ago.